Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984 Dec;26(6):802-6.
doi: 10.1128/AAC.26.6.802.

Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions

Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions

D B Lakings et al. Antimicrob Agents Chemother. 1984 Dec.

Abstract

The pharmacokinetics of cefpimizole (free acid equivalents of cefpimizole sodium), a broad-spectrum cephalosporin antibiotic, were determined after single- and multiple-dose 20-min intravenous infusions of 1, 2, and 4 g. The kinetics of single-dose administration of cefpimizole correspond to a two-compartment model with an average apparent volume of distribution of 20.0 +/- 3.5 liters, a distribution rate constant of 2.24 +/- 1.00 h-1, and a terminal rate constant of 0.358 +/- 0.036 h-1 (half-life, 1.9 h). The total body clearance was 118.6 +/- 20.2 ml/min. The primary route of elimination for cefpimizole was the renal route, with approximately 80% of the administered dose excreted as the parent compound. The elimination rate constant, as calculated from urinary excretion data, was 0.339 +/- 0.043 h-1, which is in close agreement with the terminal rate constant for plasma. Renal clearance of cefpimizole was 96.2 +/- 17.3 ml/min. Dose proportionality over the three dose levels was obtained from area under the plasma curve and cumulative urinary excretion data. The results of the multiple-dose study indicated that no apparent change in the distribution or elimination kinetics of cefpimizole occurred after the administration of 1-, 2-, and 4-g doses for 7 days, three times a day. The kinetics from the multiple-dose study were in close agreement with those from the single-dose study. No accumulation of cefpimizole occurred, and nondetectable levels was observed 24 h after administration of the last dose. Peaks that could be attributed to metabolites of cefpimizole were not observed during high-pressure liquid chromatographic analysis of either plasma or urine specimens.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nouv Presse Med. 1981 Feb 26;10(8):559-63 - PubMed
    1. J Chromatogr. 1984 Jun 8;308:261-71 - PubMed
    1. Antimicrob Agents Chemother. 1981 May;19(5):821-5 - PubMed
    1. Antimicrob Agents Chemother. 1981 Nov;20(5):634-41 - PubMed
    1. Lancet. 1982 May 22;1(8282):1152-6 - PubMed

LinkOut - more resources